Cargando…

Treatment Outcomes in Anaplastic Thyroid Cancer

BACKGROUND: Anaplastic thyroid cancer (ATC) is rare, accounting for 1-2% of thyroid malignancies. Median survival is only 3-10 months, and the optimal therapeutic approach has not been established. This study aimed to evaluate outcomes in ATC based on treatment modality. METHODS: Retrospective revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrigan, Kelsey L., Williamson, Hannah, Elliott Range, Danielle, Niedzwiecki, Donna, Brizel, David M., Mowery, Yvonne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556325/
https://www.ncbi.nlm.nih.gov/pubmed/31249658
http://dx.doi.org/10.1155/2019/8218949
_version_ 1783425312104644608
author Corrigan, Kelsey L.
Williamson, Hannah
Elliott Range, Danielle
Niedzwiecki, Donna
Brizel, David M.
Mowery, Yvonne M.
author_facet Corrigan, Kelsey L.
Williamson, Hannah
Elliott Range, Danielle
Niedzwiecki, Donna
Brizel, David M.
Mowery, Yvonne M.
author_sort Corrigan, Kelsey L.
collection PubMed
description BACKGROUND: Anaplastic thyroid cancer (ATC) is rare, accounting for 1-2% of thyroid malignancies. Median survival is only 3-10 months, and the optimal therapeutic approach has not been established. This study aimed to evaluate outcomes in ATC based on treatment modality. METHODS: Retrospective review was performed for patients treated at a single institution between 1990 and 2015. Demographic and clinical covariates were extracted from the medical record. Overall survival (OS) was modeled using Kaplan Meier curves for different treatment modalities. Univariate and multivariate analyses were conducted to assess the relationships between treatment and disease characteristics and OS. RESULTS: 28 patients with ATC were identified (n = 16 female, n = 12 male; n = 22 Caucasian, n = 6 African-American; median age 70.9). Majority presented as Stage IVB (71.4%). Most patients received multimodality therapy. 19 patients underwent local surgical resection. 21 patients received locoregional external beam radiotherapy (EBRT) with a median cumulative dose of 3,000 cGy and median number of fractions of 16. 14 patients received systemic therapy (n = 11 concurrent with EBRT), most commonly doxorubicin (n = 9). 16 patients were never disease free, 11 patients had disease recurrence, and 1 patient had no evidence of disease progression. Median OS was 4 months with 1-year survival of 17.9%. Regression analysis showed that EBRT (HR: 0.174; 95% CI: 0.050–0.613; p=0.007) and surgical resection (HR: 0.198; 95% CI: 0.065–0.598; p=0.004) were associated with improved OS. Administration of chemotherapy was not associated with OS. CONCLUSIONS: Anaplastic thyroid cancer patients receiving EBRT to the thyroid area/neck and/or surgical resection had better OS than patients without these therapies, though selection bias likely contributed to improved outcomes since patients who can undergo these therapies tend to have better performance status. Prognosis remains poor overall, and new therapeutic approaches are needed to improve outcomes.
format Online
Article
Text
id pubmed-6556325
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65563252019-06-27 Treatment Outcomes in Anaplastic Thyroid Cancer Corrigan, Kelsey L. Williamson, Hannah Elliott Range, Danielle Niedzwiecki, Donna Brizel, David M. Mowery, Yvonne M. J Thyroid Res Research Article BACKGROUND: Anaplastic thyroid cancer (ATC) is rare, accounting for 1-2% of thyroid malignancies. Median survival is only 3-10 months, and the optimal therapeutic approach has not been established. This study aimed to evaluate outcomes in ATC based on treatment modality. METHODS: Retrospective review was performed for patients treated at a single institution between 1990 and 2015. Demographic and clinical covariates were extracted from the medical record. Overall survival (OS) was modeled using Kaplan Meier curves for different treatment modalities. Univariate and multivariate analyses were conducted to assess the relationships between treatment and disease characteristics and OS. RESULTS: 28 patients with ATC were identified (n = 16 female, n = 12 male; n = 22 Caucasian, n = 6 African-American; median age 70.9). Majority presented as Stage IVB (71.4%). Most patients received multimodality therapy. 19 patients underwent local surgical resection. 21 patients received locoregional external beam radiotherapy (EBRT) with a median cumulative dose of 3,000 cGy and median number of fractions of 16. 14 patients received systemic therapy (n = 11 concurrent with EBRT), most commonly doxorubicin (n = 9). 16 patients were never disease free, 11 patients had disease recurrence, and 1 patient had no evidence of disease progression. Median OS was 4 months with 1-year survival of 17.9%. Regression analysis showed that EBRT (HR: 0.174; 95% CI: 0.050–0.613; p=0.007) and surgical resection (HR: 0.198; 95% CI: 0.065–0.598; p=0.004) were associated with improved OS. Administration of chemotherapy was not associated with OS. CONCLUSIONS: Anaplastic thyroid cancer patients receiving EBRT to the thyroid area/neck and/or surgical resection had better OS than patients without these therapies, though selection bias likely contributed to improved outcomes since patients who can undergo these therapies tend to have better performance status. Prognosis remains poor overall, and new therapeutic approaches are needed to improve outcomes. Hindawi 2019-05-23 /pmc/articles/PMC6556325/ /pubmed/31249658 http://dx.doi.org/10.1155/2019/8218949 Text en Copyright © 2019 Kelsey L. Corrigan et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Corrigan, Kelsey L.
Williamson, Hannah
Elliott Range, Danielle
Niedzwiecki, Donna
Brizel, David M.
Mowery, Yvonne M.
Treatment Outcomes in Anaplastic Thyroid Cancer
title Treatment Outcomes in Anaplastic Thyroid Cancer
title_full Treatment Outcomes in Anaplastic Thyroid Cancer
title_fullStr Treatment Outcomes in Anaplastic Thyroid Cancer
title_full_unstemmed Treatment Outcomes in Anaplastic Thyroid Cancer
title_short Treatment Outcomes in Anaplastic Thyroid Cancer
title_sort treatment outcomes in anaplastic thyroid cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556325/
https://www.ncbi.nlm.nih.gov/pubmed/31249658
http://dx.doi.org/10.1155/2019/8218949
work_keys_str_mv AT corrigankelseyl treatmentoutcomesinanaplasticthyroidcancer
AT williamsonhannah treatmentoutcomesinanaplasticthyroidcancer
AT elliottrangedanielle treatmentoutcomesinanaplasticthyroidcancer
AT niedzwieckidonna treatmentoutcomesinanaplasticthyroidcancer
AT brizeldavidm treatmentoutcomesinanaplasticthyroidcancer
AT moweryyvonnem treatmentoutcomesinanaplasticthyroidcancer